[A20-43] Darolutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 03.08.2020
Project no.:
A20-43
Commission:
Commission awarded on 30.04.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Indication:
Adults with non-metastatic castration-resistant prostate cancer who are at high risk of developing metastatic disease
Result of dossier assessment:
Indication of considerable added benefit
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A20-84 | Darolutamide (prostate cancer) - Addendum to Commission A20-43 | Commission completed |